Systemic mastocytosis (SM) is a stem-cell-derived clonal myeloproliferation characterized by an accumulation of abnormal mast cells. A majority of SM patients harbor the KITD816V mutation, indicating its potentially important role in disease pathogenesis. KITD816V activates several downstream signaling pathways including PI3-kinase/AKT, STAT5 and ERK-1/2 that mediate its proliferative, survival and differentiation effects. SRC family kinases have an important role in stem cell factor (SCF)-induced cell proliferation; in SCF-responsive cell lines and hematopoietic progenitor cells, LYN is associated with the juxtamembrane region of KIT, and is rapidly phosphorylated in response to SCF stimulation. 1 Coexpression of KIT with functionally defective CBL, normally a negative regulator of KIT, in murine bone marrow cells leads to generalized mastocytosis. 2 Interestingly, KIT kinase activity was dispensable for cell transformation mediated by mutant CBL; instead, transformation was dependent on the SRC family kinase, FYN. Furthermore, recent data suggest that SRC kinase activity is important for full expression of KITD816V's transforming potential; KITD816V not only activates receptor kinase activity, but also subverts its substrate specificity to confer SRC-like Letters to the Editor kinase activity.
3 JAK2 also appears to be an integral component of the SCF/KIT signaling pathway; in SCF-responsive MO7e cells, JAK2 is constitutively associated with KIT in unstimulated cells; SCF stimulation results in recruitment of JAK2 to the KIT receptor complex, and induces rapid phosphorylation of the former. 4 Furthermore, JAK2 knockdown with antisense oligonucleotides resulted in marked inhibition of SCF-induced cell proliferation, thereby confirming its key role in the SCF/KIT signaling cascade.
Current therapy of SM is suboptimal and includes interferon-a and 2-chlorodeoxyadenosine, which are capable of achieving mast cell cytoreduction (reviewed by Pardanani and Tefferi 5 ). Although several drugs have demonstrable anti-KIT activity in vitro, their clinical benefit to date has been limited. Imatinib mesylate, a KIT inhibitor, does not inhibit KITD816V, but has activity against other rare SM-relevant KIT mutations, such as KITF522C (transmembrane domain) and KITV560G (juxtamembrane domain); consequently, it appears to have a limited role for the treatment of adult SM. Dasatinib inhibits both juxtamembrane and activation-loop KIT mutants in vitro, and in addition has anti-SRC activity; it has limited activity, however, in the treatment of SM patients and clinical responses are mostly limited to alleviation of symptoms.
There is currently an unmet need for effective therapies for SM. Given the aforementioned key role of JAK2 kinase in mediating SCF/KIT signaling, and the recent availability of orally bioavailable JAK2 kinase-selective small molecule inhibitors, we were interested in whether inhibition of the JAK-STAT pathway, downstream of KITD816V, would be potentially useful for the treatment of SM. Toward this end, we examined TG101348, a JAK2-selective inhibitor, 6, 7 which is currently under study for the treatment of myelofibrosis, 8 for its ability to inhibit proliferation of KITD816V-driven human mast cell leukemia cells. TG101348 is known to inhibit JAK2 potently (enzyme IC 50 ¼ 3 nM); in contrast, it does not exhibit any significant anti-KIT activity (16% enzyme inhibition at 500 nM TG101348; Pardanani A, unpublished data). Oral dosing with TG101348 in myelofibrosis patients yields dose-linear plasma exposure; at the maximum tolerated dose of 680 mg daily, the steady-state plasma concentrations range from 2-4 mM at trough to 3-7 mM at peak (unpublished data). Preliminary results show TG101348 to be well tolerated in patients with myelofibrosis; many patients experience clinically meaningful responses that are associated with decreasing JAK2V617F allele burden. 8 Finally, we were also interested in whether inhibition of SRC family kinases would be synergistic with JAK2 inhibition, for abrogating KITD816V-driven cell proliferation. Toward this end, we studied the combination of TG101348 with dasatinib in the aforementioned experimental approach.
TG101348 was provided by TargeGen Inc. (San Diego, CA, USA). Dasatinib was purchased from LC Laboratories (Woburn, MA, USA). HMC-1 cells were provided by JH Butterfield (Mayo Clinic). Antibodies obtained from Cell Signaling (Beverly, MA, USA) were the following: JAK2 (no. 3230), phospho-JAK2 (Tyr1007/1008), STAT-5 (no. 9310), phospho-STAT-5 (Tyr694), STAT-3 (no. 9139), phospho-STAT-3 (Tyr705), b-actin, antimouse horseradish peroxidase-linked IgG and anti-rabbit horseradish peroxidase-linked IgG. Antibodies obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA) were c-KIT (sc-168) and phospho-c-KIT (Tyr568/570). Cell proliferation (XTT) analysis was performed as previously described. 9 Western blot analysis was performed as previously described except that cells were treated with inhibitor for 4 h before harvesting. Letters to the Editor decreased activity against HMC-1.2 cells (IC 50 ¼ 15 mM). Dasatinib inhibited proliferation of both cell lines, albeit with 2-3 log less potency against HMC-1.2 as compared to HMC-1.1 (IC 50 ¼ 308 and 1 nM, respectively). We found KIT and JAK2 to be constitutively phosphorylated in HMC-1.1 and HMC-1.2 cells, in the absence of exogenous cytokines (Figure 1) . Consistent with observations from aforementioned in vitro enzyme assays, TG101348 did not inhibit phosphorylation of KITV560G or KITD816V within the context of the two HMC-1 clones at concentrations up to 25 mM (Figure 1, top panel) . In contrast, imatinib mesylate potently inhibited the kinase activity of KITV560G, but not KITD816V, with IC 50 for receptor phosphorylation of o150 and 425 mM, respectively (Figure 1, bottom panel) . Imatinib did not inhibit JAK2 phosphorylation, however, in either HMC-1 clone at up to high micromolar concentrations (Figure 1, bottom panel) . TG101348 potently inhibited JAK-STAT signaling in HMC-1.2 cells, the IC 50 for JAK2 phosphorylation was 150 and 600 nM (lower and upper phospho-JAK2 bands, respectively); the IC 50 for STAT-5 and STAT-3 phosphorylation was B600 nM (Figure 1 In summary, we have shown the viability of targeting JAK-STAT signaling downstream of KITD816V in human mast cell leukemia cells as a potentially novel therapeutic approach in SM. Our experience to date with currently available JAK2-selective drugs, such as TG101348, which are orally bioavailable and have a favorable safety profile, leads us to believe that clinical trials with such agents for SM therapy are warranted. Recent clinical experience with TG101348 has shown that it is feasible to achieve serum drug concentrations that are predicted, based on our data, to be therapeutically relevant in SM. The concurrent use TG101348 and dasatinib targets known signaling pathways of major pathogenetic relevance in SM, namely KIT, JAK-STAT and SRC; this approach is clinically feasible given the synergy between the two drugs that should permit therapeutic activity to be manifest at doses that are lower than those used as monotherapy, thereby preserving an overall favorable therapeutic safety profile. With the double aim of reducing the toxicity of the autograft procedure by using peripheral blood stem cells and granulocyte colony-stimulating factor, and decreasing the relapse rate of acute myeloid leukemia (AML) patients after autologous hematopoietic stem cell transplantation (auto-HSCT) by delivering a higher dose of chemotherapy, the GOELAMS undertook in 2001 a phase III prospective randomized trial to assess the
